1- Tuncer E. Geropsikiyatri. I Sayılı (ed): Ruh Sağlığı ve Hastalıkları’nda. Birinci baskı, ANTIP Yayınları Ankara, 2000: 595-606.
2- Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recom-mendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005; 55: 241-252
3- Pegram MD, Casciato DA. Breast cancer. İn: Casciato DA. Manual of clinical oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2009: 237–
262.
4- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;
60: 277–300.
5- Cancer Surveillance, Surveillance and Health Policy Research, American Cancer Society, Atlanta, GA 30303-1002, USA.
6- Matthew D Barber, Jeremy St J Thomas, J Michael Dixon. An Atlas of Investigation and Management Breast cancer. 2008: 50-53.
7- Tuncer M. Significance of cancer in Turkey, the burden of diseaseand cancer control policies (Volume 74). In: Tuncer M.eds. Cancer Control in Turkey, Ankara, Onur Press, Health Ministry Publication. 2008: 5-9.
8- Anbarcıoğlu Z, Ergün A, Akın Ü ve ark. Nüfus Tabanlı Kanser Kayıt Merkezleri Veri Havuzu Sekiz İl, 2004–2006 Değerlendirmesi.
9- Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001; 40 : 133–140.
10- Cancer Statistics Review 1975-2005. Surveillance, Epidemiology and End Results (SEER) Program. 2005.
103
11- Berry DA, Cronin KA, Plevritis SK, et al. Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005 ; 353: 1784–1792.
12- Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996 ; 347:1713–1727.
13- Garber J. Breast cancer. In: Silva EO, Zumda S (eds.). Risk Factors. 3rd ed.
Oxford: Elsevier Saunders, 2005. 26–53.
14- Colditz GA, Willett WC, Hunter DJ,et al. Family history, age, and risk of breast cancer. JAMA. 1993; 270: 338-343.
15- Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk: The Utah population data-base. JAMA. 1993; 270:1563-1568.
16- Conzen SD, Grushko TA, Olopade OI. Cancer of the Breast. Section 1: The Molecular Biology of Breast Cancer. İn: De Vita VT, Lawrence TS, Rosenberg SA, eds. Cancer Principles&Practice of Oncology, 8th ed. Philadelphia:
Lippincott Williams & Wilkins, 2008: 1595–1605.
17- Smith AW, Alfano CM, Reeve BB, et al. Race/ethnicity, physical activity, and quality of life in breast cancer survivors. Cancer Epidemiol Biomarkers Prev.
2009; 18: 656- 663.
18- Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007; 25: 2671-2677.
19- Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353: 1993-2000.
104
20- Kelsey JL, Fischer DB, Holford TR, et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst. 1981; 67: 327-333
21- Maruti SS, Willett WC, Feskanich D, et al. A prospective study of age-specific physical activity and premenopausal breast cancer. Natl Cancer Inst. 2008;100:
728-737.
22- Eliassen AH, Colditz GA, Rosner B, et al. Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006; 296:193-201.
23- Winstanley MH, Pratt IS, Chapman K, et al. Alcohol and cancer: a position statement from Cancer Council Australia. Med J Aust. 2011;194: 479-482.
24- Cho E, Chen WY, Hunter DJ, et.al. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med. 2006; 166: 2253-2259.
25- Shin MH, Holmes MD, Hankinson SE, et.al. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst. 2002 ;94:1301-1311.
26- Band PR, Le ND, Fang R, et al. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet. 2002; 360 :1044-1049.
27- John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev . 1993; 15: 157-162.
28- McCormack VA, Dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159.
29- Stenberg SS. Diagnostic Surgical Pathology, 3rd ed. Vol I Philedelphia, Lippincot Williams and Wilkins,1999; 319–379
105
30- Gabos Z, Thoms J, Ghosh S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 2010; 124:187-194
31- Tavasolli FA, Devilee P. Pathology and Genetics of the Breast and Female Genital Organs. In: World Health Organition Classification of Tumours.
Tavasolli FA, Devilee P (eds). Lyon; IARC Press, 2003. 9–113
32- Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355-560
33- Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics. 2006; 7-96.
34- Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A.
2003; 100:8418.
35- Sotiriou C, Neo SY, Mc Shane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Proc Natl Acad Sci USA. 2003; 100:10393.
36- Yu K, Lee CH, Tan PH, et al. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res. 2004; 10:5508.
37- Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;
64:830.
38- Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28:1684.
106
39- Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95:
1482.
40- Olopade OI, Grushko T. Gene-expression profiles in hereditary breast cancer.
N Engl J Med 2001; 344:2028.
41- Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res .2010; 12: 68.
42- Burstein H J, Harris JR, Morrow M. Cancer of the Breast. Section 2: Malignant Tumors of the Breast. İn: De Vita V T, Lawrence TS, Rosenberg SA, eds.
Cancer Principles&Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1606–1654
43- National Comprehensive Cancer Network (NCCN) Guidelines Version 2.
2011.
44- Veronesi U. Conservation surgery and irradiation in stages 1 and 2 disease.
European experience. In: Bland KI, Copeland EM (eds.) The Breast:
Comprehensive management of benign and malignant diseases. 2nd ed.
Philedelphia: W.B. Saunders; 1998. p1191–1196.
45- Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or vvithout irradiaton in the treatment of Breast cancer.
N Engl J Med. 1995;333:1456–1461.
46- Cuzick J, Stewart H, Peto R, et al. Cause spesifıc mortality in long term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. l994; 12: 447–453.
47- Fowble M. Local-regional treatment options for early invasive breast cancer, In: Fowble B, Goodman RL, Glick JH (eds.). Breast cancer treatment-A
107
comprehensive guide to management. St Louis: Mosby Yearbook, 1991:404–
408.
48- Perez CA, Garcia DM, Kuske RR, Levitt SH. Breast: Stage Tl and T2 Tumors, In: Perez CA, Brady LW (eds.). Principles and practice of radiation oncology.
Philadelphia: JB Lippincott; 1992: 877–947.
49- Veronesi U, Luini A, Galimberti V, et al. Conservation approaches for the management of stage I-II carcinoma of the breast. Milan Cancer Instute Trials.
World J Surg. 1994; 18: 70–75.
50- Upsala-Orebro Breast Cancer Study Group: Sector resection with or without postoperative radiotherapy for stage I breast cancer. A randomised trial. J Natl Cancer Inst 1990; 82: 277-282.
51- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;
365:1687–1717.
52- Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Clin Oncol. 2003; 21 : 976–983.
53- Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:
results from NSABP B-28. J Clin Oncol. 2005; 23: 3686-3696.
54- Wolowacz SE, Cameron DA, Tate HC, et al. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008 ; 26 : 925-933.
55- Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or
108
weekly in patients with axillary node positive of high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199.
Breast Cancer Res Treat. 2005; 94 (suppl 1).
5 Shulman LN, et al.San Antonio Breast Cancer Symposium 2010. Abstract S 6-3.
57- Atalay G, Cardoso F, Awada A, et al. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Annals of Oncology. 2003; 14: 1346–63
58- Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Oncologist. 2009;14: 320–368.
59- Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;
353: 1673–1684.
60- Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–726.
61- Valero V, Forbes J, Pegram MD, et al. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. J Clin Oncol. 2011;29:149-156
62- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001 ;344:783–792.
63- Burris H III, Yardley D, Jones S, et al Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22: 1621–1629.
109
64- Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol.
2005; 23: 4265–4274.
65- Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB -2 tyrosine kinase inhibitor,GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85–94.
66- Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998; 20: 41–48.
67- Okano J, Gaslightwala I, Birnbaum MJ, et al. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 2000; 275: 30934–30942.
68- Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008; 112: 533–543.
69- Rugo HS, Franco S, Munster P,et al. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). J Clin Oncol.
2008;26: 1042
70- Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. J Clin Oncol.2008; 26: 1016
71- Janni W, Von Minckwitz G, Möbus V,et al . Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast Care (Basel). 2008;3(s1):17-20.
110
72- Miller K, Wang M, Gralow J,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666–
2676.
73- Hamilton EP, Blackwell KL. Safety of Bevacizumab in Patients with Metastatic Breast Cancer. Oncology. 2011; 80: 314–325.
74- Jubb AM, Miller KD, Rugo HS et al. Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clin Cancer Res. 2011 ;17: 372-381.
75- Campissi J. Proliferative senescence and cancer. In: Balducci L, Lyhman GH, Ershler WB, Extermann M, editors. Comprehensive Geriatric Oncology.
London and New York, Taylor - Francis, 2004: 127-37.
76- Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1. 2003:18-24.
77- Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci .2001; 56: 46-56.
78- Balducci L. Aging, frailty, and chemotherapy. Cancer Control.2007; 14: 7-12.
79- Kristjanson SR, Wyller TB. Introduction.Section 1 in : Schrijvers D, Aopro M, Zakotnik B, Audisio R, Van Haltren H, Hurria A. Esmo Handbook of Cancer in the Senior Patient. First published. London and New York: Informa Health Care. 2010:1-7.
80- Şimşir IY, Akçiçek F. Geriatrik hastalarda fizik muayene ve laboratuvar değerlendirmesi. Kutsal YG, ed. Temel Geriatri. Ankara: Güneş Tıp Kitabevleri, 2007:121-123.
81- Castiglione M, Gelber RD, Goldrich A. Adjuvan systemic therapy for breast cancer in elderly: Competing Causes of mortality. International Breast cancer Study Group. J Clin Oncol.1990; 8: 519-526.
111
82- Yancik R, Wesley MN, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;
285:885– 892.
83- Walter LC, Brand RJ, Counsell SR et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization.
JAMA. 2001; 285: 2987–2994.
84- Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 :189–198.
85- Lin KN, Wang PN, Chen C et al. The three-item clock-drawing test: a simplified screening test for Alzheimer's disease. Eur Neurol. 2003; 49:53-58.
86- Johnston B. Geriatric assessment. Landefeld CS, Palmer RM, Johnson MA, et al eds. Current Geriatric Diagnosis and Treatment. McGraw-Hill, 2004:16-26 87- Cassel CK: Geriatric Medicine. An Evidence-Based Approach. 4. baskı. New
York: Springer. 2006:149-21
88- Lebowitz BD, Pearson JL, Schneider LS. Diagnosis and treatment of depression in late life. Consensus statement update. JAMA 1997; 278:1186-1190
89- Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res.
1983; 17:37-49.
90- Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression Scale: a comparison with the 30-item form. J Geriatr Psychiatry Neurol. 1991; 4:173-178.
91- Savaş S, Akçiçek F.Kapsamlı Geriatrik Değerlendirme. Ege Tıp Dergisi. 2010.
Ek 19-30.
112
92- Soriano RP. The comprehensive geriatric assessment. Soriano RP ed.
Fundamentals of Geriatric Medicine. New York: Springer. 2007:20-38
93- Bernabei R, Venturiero V, Tarsitani P, Gambassi G. The comprehensive geriatric assessment: when, where, how. Crit Rev Oncol Hematol. 2000; 33:45-56.
94- Katz S, Downs TD, Crash H, et al. Progress in development of the index of ADL. Gerontologist 1970; 10:20-30 .Shelkey M, Wallace M. Katz Index of independence in activities of daily living. J Gerontol Nurs. 1999; 25: -9.
95- Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
96- Shelkey M, Wallace M. Katz Index of independence in activities of daily living. J Gerontol Nurs. 1999; 25 :8-9.
97- Reuben DB, Solomon DH. Assessment in geriatrics of caveats and names. J Am Geriatr Soc 1989; 37:570-572.
98- Ferrer A, Formiga F, Ruiz D. Predictive items of functional decline and 2-year mortality in nonagenarians--the NonaSantfeliustudy. Eur J Public Health 2008;
18:406-409.
99- Giannakouris K. Ageing characterises the demographic perspectives of the European societies. Population and social conditions. Eurostat Stat Focus.
2010;72 /2008.
100- Ferlay J, Autier P, Boniol M, et al. Esti- mates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18 : 581–592.
101- Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review 1975-2006. Bethesda, MD: National Cancer Institute; 2010.
113
102- Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003; 45: 313–325.
103- Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8: 1101–1115.
104- Balducci L, Exterman M,Carreca İ, Manegemant of Breast cancer in the older women . Cancer Control. 2001; 8:431-441.
105- Muss HB.Coming of Age: Breast Cancer in Seniors.The Oncologist.
2010;15:57–65
106- Biganzoli L. Breast Cancer İn the senior Patient .Section 12 in : Schrijvers D, Aopro M, Zakotnik B, Audisio R, Van Haltren H, Hurria A. Esmo Handbook of Cancer in the Senior Patient. First published . London and New York:
Informa Health Care, 2010:92-97.
107- Serugo B, Amir E, Tannock IF. Hormonal Anticancer Treatment in the senior Patient .Section 7 in : Schrijvers D, Aopro M, Zakotnik B, Audisio R, Van Haltren H, Hurria A. Esmo Handbook of Cancer in the Senior Patient. First published . London: Informa Health Care, 2010: 46-56.
108- Hébert-Croteau N, Brisson J, Latreille J et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol. 2004; 22: 3685–3693.
109- Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Cochrane Database Syst Rev(1): CD004272
110- Stearns V, Hayes DF, Jin Y, et al. The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen. Proc Am Soc Clin Oncol. 2004; 22: 508.
114
111- Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008; 9: 45–53.
112- Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1–98 trial. J Clin Oncol.2008; 26:1972-1979
113- Coombes RC, Kilburn LS, Snowdon CF, et al. Intergroup Exemestane Study Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559–70; Erratum in: Coombes RC, Kilburn LS, Snowdon CF, et al.
Lancet 2007;369:906.
114- Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality oflife in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup Trial MA.17. J Clin Oncol.
115- Visvanathan K, Chlebowski RT, Hurley P et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009; 27: 3235–3258.
116- Adjuvant! Online. Available at http://www.adjuvantonline.com/index.jsp, accessed April 26, 2010.
117- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371:29–40
118- Muss HB, Berry DA, Cirrincione CT et al.; CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med.
2010; 360: 2055–2065.
115
119- Piccart-Gebhart MJ, Procter M, Leyland-Jones B,et al.Trastuzumab after Adjuvant Chemotherapy in Her2-Positive Breast Cancer.The New England Journal Medicine 2005; 353:1659-1672.
120- Perez EA, Romond E H, Sumon JS, et al. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. J Clin Oncol .2011; 29: 3366-3373.
121- Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005; 293:
1073–1081.
122- Medicine Net.com. What are the complications and effects of menopause on chronicmedicalconditions?<http://www.medicinenet.com/menopause/page4.ht m> [Accessed 14.04.2008].
123- Perrone MA, Musolino A, Michiara M, et al. Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phase. Tumori. 2004; 90: 276-279.
124- Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-593.
125- Oken MM, Creech RH, Tormey DC,et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649–655 126- Lehmann-Che J, Amira-Bouhidel F, Turpin E, et al. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer. 2011; 104: 1739-1746.
127- Lowitz BB, Casciato DA. Principles, Definitions, and Statistics. İn: Casciato DA. Manual of clinical oncology,6th ed. Philadelphia: Lippincott Williams &
Wilkins, 2009: 3–18.
116
128- Tuna S. Kanserli geriatrik hastalarda komorbidite ve klinik değerlendirme.
Türk Onkoloji Dergisi. 2007, Cilt 22, Sayı 4, Sayfa(lar) 192-196.
129- National Cancer İnstitute. Cancer Statistics Review 1975-2005. Surveillance, Epidemiology and End Results (SEER) Program, April 26, 2010.
130- Sant M. Differences in stage and therapy for breast cancer across Europe. Int J Cancer. 2001; 93: 894–901.
131- Jimeno A, Amador ML, González-Cortijo L, Tornamira MV, Ropero S, Valentín V, et al. İnitially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma Cancer. 2004;100: 1833–1842.
132- Sezgin C, Zekioğlu O, Gökmen E. İlk tanıda metastatik meme kanseri ile başvuran hastaların sağkalımını etkileyen prognostik faktörler.Türk Onkoloji Dergisi. 2006; 21: 20–25.
133- Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al.
Prognostic factors in 1,038 women with metastatic breast cancer.Ann Oncol.
2008; 12: 2012–2019
134- Fratino L, Serraino D,Monfardini S. Breast cancer in 70 years old and older women.Cancer control.2001; 8: 431-441
135- Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old:Tümör characteristics, treatement choices, and survival. J Clin Oncol.2010;
28: 2038-2045.
136- Giordano SH, Buzdar AU, Smith TL, et al. Is Breast Cancer Survival İmproving? Cancer. 2004; 100: 44–52.
137- Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, et al.
Breast surgery in stage IV breast cancer: impact of staging and patient selection
Breast surgery in stage IV breast cancer: impact of staging and patient selection